Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.55 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
| ▸ | UBLCP1 | Q8WVY7 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670215 | 0.83 | PTPN11 (0.51) | PTPN11PTPROSTAT3 | |
| SCHEMBL1736062 | 0.82 | PTPN11 (0.55) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL1734774 | 0.79 | PTPN11 (0.66) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL1734576 | 0.76 | PTPN11 (0.62) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL1734580 | 0.75 | PTPN11 (0.69) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL2848964 | 0.74 | PTPN11 (0.60) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL13711682 | 0.73 | SLC6A4 (0.49) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL1734725 | 0.72 | PTPN11 (0.71) | PTPN11PTPROKAT8STAT3PPARA | |
| SCHEMBL1733827 | 0.71 | PTPN11 (1.00) | PTPN11PTPROKAT8STAT3MCL1 | |
| SCHEMBL1734802 | 0.71 | PTPN11 (0.89) | PTPN11PTPROKAT8STAT3MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | PTPN11 458/4885PTPRO 86/4885KAT8 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.